{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:25:49Z","timestamp":1784917549426,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.leukres.2024.107507","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T22:44:00Z","timestamp":1714085040000},"page":"107507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Efficacy and safety of flumatinib in the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase: A real-world single-center retrospective study, with a focus on premature drug discontinuation"],"prefix":"10.1016","volume":"142","author":[{"given":"Mingshan","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyue","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2024.107507_bib1","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.2174\/0929867328666211012093423","article-title":"Research status, synthesis and clinical application of recently marketed and clinical BCR-ABL inhibitors","volume":"29","author":"Xu","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.leukres.2024.107507_bib2","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107507_bib3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11899-021-00653-1","article-title":"Treatment-free remission: The new goal in CML therapy","volume":"16","author":"Atallah","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.leukres.2024.107507_bib4","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107507_bib5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamaoncol.2020.5774","article-title":"Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: A nonrandomized clinical trial","volume":"7","author":"Atallah","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.leukres.2024.107507_bib6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1158\/1078-0432.CCR-20-1600","article-title":"Flumatinib versus imatinib for Newly Diagnosed Chronic Phase Chronic myeloid leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2024.107507_bib7","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/ajh.26556","article-title":"Tyrosine kinase Inhibitor discontinuation in Chronic myeloid leukemia: Eligibility criteria and predictors of success","volume":"97","author":"Inzoli","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2024.107507_bib8","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107507_bib9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: From chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2024.107507_bib10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2019-128761","article-title":"Long-term outcomes in patients with chronic myeloid leukemia in chronic phase receiving frontline nilotinib versus imatinib: Enestnd 10-year, Analysis [J]","volume":"134","author":"Hughes","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107507_bib11","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107507_bib12","first-page":"1014","article-title":"Efficacy and safety of flumatinib in treatment of patients with chronic myeloid leukemia","volume":"31","author":"Zhang","year":"2023","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.leukres.2024.107507_bib13","first-page":"295","article-title":"Factors influencing severe cytopenia in chronic phase chronic myeloid leukemia patients receiving initial second generation tyrosine kinase inhibitors and its impact on treatment responses and outcomes]","volume":"44","author":"Li","year":"2023","journal-title":"Zhonghua Xue Ye Xue Za Zhi Zhonghua Xueyexue Zazhi"},{"key":"10.1016\/j.leukres.2024.107507_bib14","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107507_bib15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: Results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"07","key":"10.1016\/j.leukres.2024.107507_bib16","first-page":"816","article-title":"\u4e0d\u540c\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\u6cbb\u7597\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u7684\u7f51\u72b6Meta\u5206\u6790 [J]","volume":"21","author":"\u674e\u96ea, \u674e\u777f, \u674e\u7f8e\u8431","year":"2021","journal-title":"\u4e2d\u56fd\u5faa\u8bc1\u533b\u5b66\u6742\u5fd7"},{"key":"10.1016\/j.leukres.2024.107507_bib17","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1038\/leu.2010.169","article-title":"HH-GV-678, a novel selective inhibitor of bcr-abl, outperforms imatinib and effectively overrides imatinib resistance","volume":"24","author":"Luo","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107507_bib18","first-page":"636","article-title":"Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world]","volume":"43","author":"Zhao","year":"2022","journal-title":"Zhonghua Xue Ye Xue Za Zhi Zhonghua Xueyexue Zazhi"},{"key":"10.1016\/j.leukres.2024.107507_bib19","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","article-title":"Chronic Myeloid Leukemia, version 2.2021, NCCN Clinical Practice Guidelines in Oncology [J]","volume":"18","author":"Deininger","year":"2020","journal-title":"J. Natl. Compr. Canc. Netw. JNCCN"},{"key":"10.1016\/j.leukres.2024.107507_bib20","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2024.107507_bib21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107507_bib22","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3324\/haematol.2015.139899","article-title":"Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: The KID study","volume":"101","author":"Lee","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2024.107507_bib23","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): A prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2024.107507_bib24","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: Results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107507_bib25","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M17-1094","article-title":"Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: Results from a single-group, Phase 2, open-label study","volume":"168","author":"Mahon","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.leukres.2024.107507_bib26","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","article-title":"Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: The DASFREE study","volume":"61","author":"Shah","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2024.107507_bib27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107507_bib28","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.leukres.2024.107507_bib29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/hematology.2023000447","article-title":"Resistance mutations in CML and how we approach them","volume":"2023","author":"Soverini","year":"2023","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"10.1016\/j.leukres.2024.107507_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126758","article-title":"Structure-based analysis and biological characterization of imatinib derivatives reveal insights towards the inhibition of wild-type BCR-ABL and its mutants","volume":"29","author":"Yang","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.leukres.2024.107507_bib31","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s12288-022-01585-3","article-title":"Efficacy of flumatinib in CML patients with F359V\/C mutation","volume":"39","author":"Gao","year":"2023","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"10.1016\/j.leukres.2024.107507_bib32","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41408-022-00742-1","article-title":"Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia","volume":"12","author":"Bidikian","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2024.107507_bib33","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1038\/s41375-022-01648-4","article-title":"ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia","volume":"36","author":"Sch\u00f6nfeld","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107507_bib34","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1182\/blood-2016-09-687889","article-title":"GATA factor mutations in hematologic disease","volume":"129","author":"Crispino","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107507_bib35","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.leukres.2017.06.009","article-title":"Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy","volume":"59","author":"Kim","year":"2017","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2024.107507_bib36","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2024.107507_bib37","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/bjh.18984","article-title":"Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha","volume":"202","author":"Irani","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2024.107507_bib38","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/bjh.19013","article-title":"Interferon in chronic myeloid leukaemia: Is it useful for treatment-free remission?","volume":"202","author":"Breccia","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2024.107507_bib39","article-title":"Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia","volume":"13","author":"Jiang","year":"2023","journal-title":"Front. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624000730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624000730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T19:43:02Z","timestamp":1720208582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624000730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":39,"alternative-id":["S0145212624000730"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107507","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of flumatinib in the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase: A real-world single-center retrospective study, with a focus on premature drug discontinuation","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107507","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107507"}}